FDA warns Thoratec over manufacturing violations
This article was originally published in Clinica
Executive Summary
Mechanical heart developer Thoratec has received a warning letter from the US FDA relating to concerns over its manufacturing practices. Specifically, the letter pertains to Thoratec's late filing of two medical device reports in response to the agency's concerns following an inspection of the firm's California manufacturing facilities in August and September 2011.